



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

			FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR			
	09/822,295	04/02/2001	Bahija Jallal	038602/1125	8862	
	759	06/22/2004		EXAM	EXAMINER	
	Beth A. Burrous FOLEY & LARDNER			HOLLERAN	HOLLERAN, ANNE L	
				ART UNIT	PAPER NUMBER	
	Washington Har 3000 K Street, N	I.W., Suite 500		1642		
	Washington, Do			DATE MAILED: 06/22/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Advison, Action	09/822,295	JALLAL ET AL.				
Advisory Action	Examiner	Art Unit	S. C.			
i	Anne Holleran	1642				
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress			
THE REPLY FILED 18 February 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a nal rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued examination (RCE) in compliance with 37 CFR 1.114.						
PERIOD FOR REPLY [check either a) or b)]						
a) The period for reply expiresmonths from the mailin b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Offictimely filed, may reduce any earned patent term adjustment. See 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Offictimely filed, may reduce any earned patent term adjustment.	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailin FILED WITHIN TWO MONTHS OF THe date on which the petition under 37 CF of extension and the corresponding amount the shortened statutory period for reply ce later than three months after the main attention and the shortened statutory period for reply the later than three months after the main three months after the main attention and the shortened statutory period for reply the later than three months after the main attention and the same attention at the same attention and the same attention and the same attention at the same attention attention at the same attention a	g date of the final rejecting HE FINAL REJECTION. R 1.136(a) and the approper or the fee. The appropriation of the fee. The appropriation is the final the	on. See MPEP opriate extension ropriate extension Office action; or			
 1. A Notice of Appeal was filed on 15 January 2004. A 37 CFR 1.192(a), or any extension thereof (37 CFR 2. The proposed amendment(s) will not be entered be 	Appellant's Brief must be filed wi R 1.191(d)), to avoid dismissal o	thin the period set for the appeal.	orth in			
		see NOTE bolow)				
(a) they raise new issues that would require further consideration and/or search (see NOTE below);						
(b) they raise the issue of new matter (see Note below);						
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
(d) they present additional claims without canceling a corresponding number of finally rejected claims.						
NOTE: <u>See Continuation Sheet</u> .						
3. Applicant's reply has overcome the following reject		anamata timakirtikal	omondmost			
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).						
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because:	reconsideration has been cons	idered but does NO	T place the			
6. The affidavit or exhibit will NOT be considered bed raised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which wer	e newly			
7. For purposes of Appeal, the proposed amendmen explanation of how the new or amended claims w	t(s) a) will not be entered or bould be rejected is provided belo) will be entered above or appended.	and an			
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed:						
Claim(s) objected to:						
Claim(s) rejected:						
Claim(s) withdrawn from consideration:						
8. ☐ The drawing correction filed on is a) ☐ app	proved or b) disapproved by	the Examiner.				
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)						
10. Other:						

Continuation Sheet (PTOL-303)

Continuation of 2. NOTE: The amendment of claim 12 (in subsection "c") causes claim 25 to lack antecedent basis with respect to a polypeptide comprising at least 95% identity to the amino acid sequence set forth in amino acid residues 1-48. This would require a new rejection under 112, 2nd.

The rejections of claims 12, 27 and 29 under U.S.C. 102(a) as being anticipated by Q93095 is maintained, because Q93095 teches a polypeptide that comprises amino acid 164-243 of SEQ ID NO: 2, which would anticipate claim 12 (specifically 12(c) and 12(d)), 27 and 29. Q93095's sequence comprising amino acid 164-243 is the same as a sequence that is at least 90% identical over any part of 49-807 of SEQ ID NO: 2. The rejection of claims 12, 27 and 29 under 35 U.S.C. 102(b) as anticipated by Matthews is maintained because Matthews teaches a polypeptide comprising 89-120 of SEQ ID NO: 2, which anticipates claim 12 (specifically 12(b), 12(c) and 12(d)), 27 and 29. The rejection of claim 12, 27, 29, 31, 33 and 34 under 35 U.S.C. 102(e) is maintained, because Cheng teaches a polypeptide that comprises 790-802 of SEQ ID NO: 2 and because Cheng teaches a polypeptide that is at least 90% identical to a sequence of 24-294 of SEQ ID NO: 2. Cheng also teaches polypeptides fused to a GST polypeptide and pharmaceutical compositions. Additionally, the proposed amendment introduces new matter into the specification because the proposed claims would be drawn to polypeptides comprising fragments of a PTP04 polypeptide that do not have enzymatic activity. Please refer to advisory action mailed 1/20/2004. Also, it is noted that the second proposed after-final amendment contains a change that is not underlined, but was underlined in the after-final amendment filed 10/10/2003 that was not entered.

ALANA M. HARRIS, PH.D.
PRIMARY EXAMINER
6 7 7884